World Journal of Pharmaceutical Science and Research
www.wjpsronline.com
Review Article
ISSN: 2583-6579
SJIF Impact Factor: 5.111
Year - 2024
Volume: 3; Issue: 5
Page: 58-62

INTERSECTING CONDITIONS: NEUROFIBROMATOSIS WITH NEUROCUTANEOUS MELANOSIS, AND ITS MANIFESTATIONS – A REVIEW

Siddhi Patel[1], Dhruv Nitinkumar Soni*[2], Kapadia Sakshi Tusharbhai[3], Patel Piyal Hiteshkumar[4]

Pharm.D 5th Year, Anand Pharmacy College, Anand, Gujarat, India.

Article Received: 24 July 2024 | | ***Article Revised: 15 August 2024*** | | ***Article Accepted: 06 September 2024***

***Corresponding Author: Dhruv Nitinkumar Soni**
Pharm.D 5th Year, Anand Pharmacy College, Anand, Gujarat, India.
DOI: https://doi.org/10.5281/zenodo.13869228

How to cite this Article: Siddhi Patel, Dhruv Nitinkumar Soni, Kapadiya Sakshi Tusharbhai, Patel Piyal Hiteshkumar (2024). INTERSECTING CONDITIONS: NEUROFIBROMATOSIS WITH NEUROCUTANEOUS MELANOSIS, AND ITS MANIFESTATIONS – A REVIEW. World Journal of Pharmaceutical Science and Research, 3(5), 58-62. https://doi.org/10.5281/zenodo.13869228

ABSTRACT

Neurofibromatosis, Neurocutaneous Melanosis, and Giant Congenital Melanocytic Nevus are rare and complex conditions that often present significant diagnostic and therapeutic challenges. Neurofibromatosis (NF) is a genetic disorder characterized by the development of multiple benign tumors of the nerves and skin, as well as other abnormalities such as bone deformities and learning disabilities. Neurocutaneous Melanosis (NCM) is a rare congenital condition marked by the presence of melanocytic nevi in the skin and melanocytic tumors in the central nervous system. Giant Congenital Melanocytic Nevus (GCMN) refers to large pigmented skin lesions present at birth, which carry a risk of malignant transformation and are often associated with psychological and physical complications. This review aims to provide a comprehensive analysis of these interrelated disorders, focusing on their clinical manifestations, pathophysiology, diagnostic criteria, and treatment options.

KEYWORDS: Neurocutaneous Melanosis, Melanocytic Nevi, Melanocytosis, Neurofibromatosis, Giant Congenital Melanocytic Nevus.

INTRODUCTION

Neurocutaneous melanocytosis (NCM) is an uncommon congenital disorder identified by the presence of large or multiple congenital melanocytic nevi (CMN) combined with melanocytic infiltration of the central nervous system (CNS). First described in the early 20th century, NCM represents a complex neurocutaneous syndrome that can manifest in various forms. The most prominent feature is a solitary Giant Congenital Melanocytic Nevus (GCMN), often accompanied by multiple smaller satellite nevi. Alternatively, the condition may present with multiple congenital melanocytic nevi (MCMN) without a dominant giant nevus. An important aspect of NCM is the infiltration of melanocytes into the leptomeninges, which can lead to neurological complications such as seizures, hydrocephalus, or even malignant transformation into melanoma.[1,2] GCMN, defined as a congenital melanocytic nevus exceeding 20 cm

in diameter, is associated with significant morbidity due to its size, potential for malignant transformation, and psychological impact. The presence of GCMN, especially when associated with neurological symptoms, necessitates a high index of suspicion for NCM. The genetic basis of these conditions often involves somatic mutations in the NRAS or BRAF genes, which are also implicated in other neurocutaneous syndromes such as Neurofibromatosis Type 1 (NF1).[3,4]

Pathophysiology and Genetic Basis

The pathogenesis of NCM involves abnormal migration and proliferation of melanocytes, which originate from neural crest cells, into the CNS. This melanocytic infiltration, known as melanocytosis, can manifest either as a diffuse or nodular pattern within the leptomeninges. In patients with NCM, the presence of large or multiple CMN increases the risk of CNS involvement, potentially leading to the development of melanocytic tumors. The genetic mutations most commonly associated with NCM and GCMN are found in the NRAS and BRAF genes, which play a critical role in cell growth and differentiation.[5]

The intersection between NF and NCM is particularly intriguing, as both conditions share a common embryological origin from neural crest cells. NF1 is caused by mutations in the NF1 gene, which encodes neurofibromin, a tumor suppressor protein that regulates cell proliferation. In contrast, NCM and GCMN are often linked to somatic mutations in NRAS or BRAF, leading to constitutive activation of the MAPK pathway and uncontrolled melanocyte proliferation.[6] This shared origin from neural crest cells may account for the overlapping clinical features and the increased risk of malignancy in these patients.

Clinical Manifestations

Neurofibromatosis Type 1 (NF1) is characterized by the development of multiple neurofibromas, café-au-lait spots, Lisch nodules, and skeletal abnormalities such as scoliosis and tibial dysplasia. Patients with NF1 may also present with learning disabilities, attention deficit hyperactivity disorder (ADHD), and an increased risk of developing malignant peripheral nerve sheath tumors (MPNSTs). The presence of optic pathway gliomas and other CNS tumors is also a common feature of NF1.[7]

Neurocutaneous Melanosis (NCM) typically presents with neurological symptoms such as seizures, hydrocephalus, or cranial nerve palsies, particularly in patients with large or multiple CMNs. The diagnosis of NCM is often based on the clinical presentation and imaging findings, with MRI being the preferred modality for detecting melanocytic infiltration of the CNS. In some cases, a biopsy may be necessary to confirm the diagnosis and rule out malignancy. The prognosis of NCM is variable, with some patients remaining asymptomatic, while others may develop life-threatening complications.[8,9]

Giant Congenital Melanocytic Nevus (GCMN) is a significant dermatological condition due to its size, potential for malignant transformation, and psychological impact. GCMNs are typically brownish, hyperpigmented lesions with a smooth or nodular surface, often associated with hypertrichosis. The diagnosis of GCMN is primarily clinical, though dermoscopy and histopathological examination can aid in differentiating CMN from other pigmented lesions. Histologically, CMNs are distinguished by their larger size, deeper dermal and subcutaneous extension, and unique architectural features, such as nevus cells' extension into deeper skin layers.[10]

Diagnosis

The diagnosis of NCM is typically based on clinical findings, supported by imaging studies. MRI is the most sensitive imaging modality for detecting melanocytic infiltration of the CNS, particularly when using T1-weighted sequences, which can reveal hyperintense signals indicative of melanin. The diagnostic criteria for NCM, as established by Kadonaga and Frieden in 1991, include the presence of large or multiple CMNs along with evidence of meningeal melanosis or melanoma. The presence of neurological symptoms such as seizures, hydrocephalus, or cranial nerve palsies should prompt further investigation with MRI and, if necessary, biopsy.[11] In patients with GCMN, the risk of malignant transformation to melanoma is estimated to be between 5% and 10%, with most cases occurring before the age of 5. Therefore, regular follow-up with dermatological and neurological evaluations is essential. The management of GCMN typically involves surgical excision, particularly for lesions located in cosmetically or functionally critical areas such as the face or scalp. However, complete excision is often not feasible due to the size and location of the lesions, and adjuvant therapies such as laser treatment or topical agents may be required.[12]

Treatment Options

The management of NF, NCM, and GCMN requires a multidisciplinary approach, involving dermatologists, neurologists, neurosurgeons, and oncologists. In patients with NF1, treatment is primarily focused on managing symptoms and preventing complications. Surgical excision of neurofibromas may be necessary for symptomatic or cosmetically disfiguring lesions, while pharmacological therapies such as MEK inhibitors (e.g., selumetinib) have shown promise in reducing the size of plexiform neurofibromas.[13] For patients with NCM, treatment options are limited, and the prognosis is generally poor, particularly in cases with malignant transformation. Surgical resection of CNS melanocytic tumors may be considered in some cases, though the risk of recurrence is high. Adjuvant therapies such as radiation or chemotherapy may be used in cases of malignant melanoma, though the efficacy of these treatments is limited.[14] In patients with GCMN, surgical excision remains the mainstay of treatment, though the size and location of the lesions often limit the feasibility of complete excision. In such cases, partial excision combined with laser therapy or dermabrasion may be considered. Regular follow-up with dermatological and neurological evaluations is essential for early detection of malignant transformation and other complications.[15]

DISCUSSION

Giant Congenital Melanocytic Nevus (GCMN) is characterized by lesions that exceed 20 cm in diameter, especially in critical areas like the face. It occurs in about 1 in 500,000 newborns, with a higher prevalence among females. The inheritance pattern of GCMN is complex and not yet fully understood. Approximately 82% of GCMNs are distributed axially, affecting regions such as the head, trunk, and neck. GCMN typically presents as a brownish lesion with a smooth or slightly bumpy texture, well-defined borders, and hypertrichosis (excessive hair growth). Diagnosis of CMN is primarily based on clinical observations during a physical examination. Histologically, distinguishing congenital nevi from acquired ones depends on their larger size, the migration of nevus cells into deeper skin layers, and their unique architectural and morphological features. Neurocutaneous Melanocytosis (NCM) involves the benign or malignant proliferation of melanocytes within the central nervous system (CNS), often associated with congenital melanocytic lesions. NCM is observed in approximately 2-45% of patients with GCMNs.[16] The etiology of NCM is thought to result from developmental anomalies during neuroectoderm morphogenesis, although its exact pathogenesis remains unclear. One hypothesis suggests that irregular development of melanoblasts after fertilization, potentially originating in the neural crest of the ectoderm, leads these cells to migrate to the meninges, becoming precursors for both benign

and malignant melanocytes. Another proposed mechanism involves mutations in the NRAS gene at codon 61, which have been identified in individuals with CMNs and CNS melanocytic tumors, likely originating in the neural crest as well.[17] The diagnosis of NCM follows the criteria established by Kadonaga and Frieden in 1991. These criteria include the presence of large and/or numerous congenital melanocytic lesions along with meningeal melanosis or melanoma. For adults, "large" refers to lesions exceeding 20 cm in diameter, while for neonates and infants, the thresholds are 9 cm on the head and 6 cm on the body. "Multiple" indicates the presence of three or more lesions. The clinical and histopathological similarities between GCMN and neurofibromas are likely due to their shared origin from the neural crest, which is the precursor for both melanocytes and Schwann cells.[18]

CONCLUSION

Giant congenital melanocytic nevi (GCMNs) and neurocutaneous melanocytosis (NCM) are distinct yet interrelated cutaneous and neurological disorders originating from aberrant neural crest cell differentiation. GCMNs, characterized by extensive melanocytic proliferation with deep dermal and subcutaneous involvement, represent a significant departure from acquired nevi. Their association with NCM, a condition involving melanocytic infiltration of the central nervous system (CNS), underscores the importance of rigorous clinical monitoring for malignant transformation. The pathogenesis of NCM likely involves disruptions in melanoblast migration and proliferation, potentially linked to NRAS mutations, highlighting the intricate developmental processes underlying neuroectoderm morphogenesis. The phenotypic overlap between GCMNs, NCM, and neurofibromas emphasizes the shared neural crest origin of melanocytes and Schwann cells and the complex interactions within this lineage. A comprehensive understanding of the molecular and developmental basis of these conditions is essential for optimizing diagnostic, therapeutic, and surveillance strategies.

REFERENCES

1. Ruggieri M, Polizzi A, Catanzaro S, et al. Neurocutaneous melanocytosis (melanosis). Child's Nervous System, 2020 Oct; 36: 2571-96.
2. Viana AC, Gontijo B, Bittencourt FV. Giant congenital melanocytic nevus. An Bras Dermatol, 2013; 88: 863-78.
3. Bennett DC. Genetics of melanoma progression: The rise and fall of cell senescence. Pigment Cell Melanoma Res, 2016; 29(2): 122-140.
4. Van Raamsdonk CD, Bezrookove V, Green G, et al. Frequent somatic mutations of GNAQ in uveal melanoma and blue naevi. Nature, 2009; 457(7229): 599-602.
5. Kinsler VA, O'Hare P, Bulstrode N, et al. Melanoma in congenital melanocytic naevi. Br J Dermatol, 2017; 176(5): 1131-1143.
6. Kozyra P, Pitucha M. Revisiting the Role of B-RAF Kinase as a Therapeutic Target in Melanoma. Curr Med Chem, 2024; 31(15): 2003-2020. doi: 10.2174/0109298673258495231011065225. PMID: 37855341.
7. Ferner RE, Gutmann DH. Neurofibromatosis type 1 (NF1): diagnosis and management. Handb Clin Neurol, 2013; 115: 939-55. doi: 10.1016/B978-0-444-52902-2.00053-9. PMID: 23931823.
8. Schaff LR, Marghoob A, Rosenblum MK, Meyer R, Khakoo Y. Malignant transformation of neurocutaneous melanosis (NCM) following immunosuppression. Pediatr Dermatol, 2019 Jul; 36(4): 497-500. doi: 10.1111/pde.13804. Epub 2019 Mar 13. PMID: 30868657; PMCID: PMC6620153.
9. Di Rocco F, Sabatino G, Koutzoglou M, Battaglia D, Caldarelli M, Tamburrini G. Neurocutaneous melanosis. Childs Nerv Syst, 2004 Jan; 20(1): 23-8. doi: 10.1007/s00381-003-0835-9. Epub 2003 Oct 24. PMID: 14576958.

10. Sarkar A, Karmakar D, Saha JK, Saha Basu K, Chatterjee U, Saha K, Mishra DK. Giant Congenital Melanocytic Nevus with Congenital Neurofibroma: A Case Report. Fetal Pediatr Pathol, 2023 Dec; 42(6): 972-978. doi: 10.1080/15513815.2023.2244582. Epub 2023 Aug 16. PMID: 37584237.
11. Ramachandran H, Radhakrishnan A, Radhakrishnan SE. Neurocutaneous Melanosis: Cutaneous and Neuroimaging Findings. Neurol India, 2020 Nov-Dec; 68(6): 1508. doi: 10.4103/0028-3886.304124. PMID: 33342911.
12. Mormina E, Granata F, Vinci SL, Coglitore A, Caragliano AA, Tessitore A, Longo M, Visalli C. Imaging and Clinical Features of Neurocutaneous Melanosis in the Pediatric Population. Curr Med Imaging, 2021; 17(12): 1391-1402. doi: 10.2174/1573405617666210527091109. PMID: 34047260.
13. Jahnke MN, O'Haver J, Gupta D, Hawryluk EB, Finelt N, Kruse L, Jen M, Horii KA, Frieden IJ, Price H, Coughlin CC. Care of Congenital Melanocytic Nevi in Newborns and Infants: Review and Management Recommendations. Pediatrics, 2021 Dec 1; 148(6): e2021051536. doi: 10.1542/peds.2021-051536. PMID: 34845496.
14. Islam MP. Neurocutaneous melanosis. Handb Clin Neurol, 2015; 132: 111-7. doi: 10.1016/B978-0-444-62702-5.00007-X. PMID: 26564074.
15. Chen L, Zhai L, Al-Kzayer LFY, Sarsam SN, Liu T, Alzakar RH, Nakazawa Y. Neurocutaneous Melanosis in Association With Large Congenital Melanocytic Nevi in Children: A Report of 2 Cases With Clinical, Radiological, and Pathogenetic Evaluation. Front Neurol, 2019 Feb 7; 10: 79. doi: 10.3389/fneur.2019.00079. PMID: 30792691; PMCID: PMC6374324.
16. Slutsky JB, Barr JM, Femia AN, Marghoob AA. Large congenital melanocytic nevi: associated risks and management considerations. Semin Cutan Med Surg, 2010; 29: 79-84.
17. Gowda VK, Basude A, Srinivas SM, Bhat M. Giant melanocytic nevi with neurocutaneous melanosis masquerading as neurofibromas. Journal of Pediatric Neurosciences, 2016 Jul 1; 11(3): 258-60.
18. Kadonaga JN, Frieden IJ. Neurocutaneous melanosis: definition and review of the literature. J Am Acad Dermatol, 1991; 24: 747–55.